Articles

Moderna has filed for authorization for its COVID-19 vaccine candidate, which has shown high efficacy and safety in a Phase III trial.

Moderna Files for FDA EUA for mRNA-1273

The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products and cGMP suites for early-phase cGMP manufacture.

Lonza to Expand Particle Engineering and Drug Product Capabilities at its Oregon Site

The virtual assessments will address problems, issues, and questions customers have about their environments and operations.

Contec to Provide Virtual Contamination Control Assessments

Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters. 

Bora Pharmaceuticals Completes Acquisition of GSK’s Canadian Facility 

The added space will house a portion of its PVC, polyurethane, silicone, and additional plastic tubing products, as well as its AdvantaPure products.

NewAge Industries Expands Warehouse Capacity at its Pennsylvania Headquarters

Behzad Mahdavi, PhD, will join a team of experts in the company’s Science and Technology Group to fast-track the adoption of new development and drug delivery technologies and manufacturing processes and techniques.



Catalent Appoints New Vice President of Open Innovation, Biologics, Cell and Gene Therapy

The expansion is part of a new expansion initiative aimed at increasing flexibility, efficiency, and cost-effective production.

CordenPharma Colorado Completes Peptide Manufacturing Expansion

The companies have entered into a global collaboration and license agreement to develop zuranolone (SAGE-217) for major depressive disorder, postpartum depression (PPD), and SAGE-324 for essential tremor and other neurological disorders.

Biogen and Sage Therapeutics Enter into $3 Billion Collaboration 

FDA granted fast track designation for AB201, a small recombinant protein that is a potent, selective inhibitor of tissue factor, for the potential treatment of COVID-19. 

FDA Grants Fast Track Designation to ARCA biopharma’s Potential COVID-19 Treatment

The EC’s approval was based on positive results from a Phase III clinical trial that demonstrated a statistically significant and clinically meaningful improvement in patients compared to chemotherapy.

News